Sandbox:Preeti: Difference between revisions
Jump to navigation
Jump to search
Preeti Singh (talk | contribs) No edit summary |
Preeti Singh (talk | contribs) No edit summary |
||
Line 7: | Line 7: | ||
! colspan="2" rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | ! colspan="2" rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | ||
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | ! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | ||
! colspan=" | ! colspan="6" rowspan="2" |Clinical manifestations | ||
! colspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Paraclinical findings | ! colspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Paraclinical findings | ||
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard | ! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard | ||
Line 15: | Line 15: | ||
|- | |- | ||
! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms | ! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms | ||
! colspan=" | ! colspan="2" |Signs | ||
! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC | ! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC | ||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry | ||
Line 25: | Line 25: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Diarrhea | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Diarrhea | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mass | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mass | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |WBC | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |WBC | ||
Line 31: | Line 30: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt | ||
|- | |- | ||
! colspan=" | ! colspan="17" align="left" style="background:#4479BA; color: #FFFFFF;" + |HL | ||
|- | |- | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Hodgkin's Lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Hodgkin's Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 51: | Line 49: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! colspan=" | ! colspan="17" align="left" style="background:#4479BA; color: #FFFFFF;" + |NHL | ||
|- | |- | ||
! rowspan="12" align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma | ! rowspan="12" align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma | ||
Line 64: | Line 62: | ||
| align="center" style="background:#F5F5F5;" + |– | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Bleeding | * Bleeding | ||
Line 93: | Line 90: | ||
* Painless peripheral adenopathy in the cervical, axillary, inguinal, and/or femoral regions | * Painless peripheral adenopathy in the cervical, axillary, inguinal, and/or femoral regions | ||
* Asymptomatic large abdominal mass | * Asymptomatic large abdominal mass | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* [[Seizures]] | * [[Seizures]] | ||
Line 128: | Line 124: | ||
* Palpable masses in skin, breast, and salivary glands | * Palpable masses in skin, breast, and salivary glands | ||
* Generalized lymphadenopathy | * Generalized lymphadenopathy | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Extranodal involvement of GI tract, lungs, and CNS | * Extranodal involvement of GI tract, lungs, and CNS | ||
Line 163: | Line 158: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Painless rapidly enlarging [[lymph nodes]] | * Painless rapidly enlarging [[lymph nodes]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |↓ | | align="center" style="background:#F5F5F5;" + |↓ | ||
Line 188: | Line 182: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Diarrhea | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Diarrhea | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mass | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mass | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |WBC | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |WBC | ||
Line 217: | Line 210: | ||
* Jaw mass | * Jaw mass | ||
* [[Abdominal mass|Abdominal masses]] | * [[Abdominal mass|Abdominal masses]] | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* [[Ascites]] | * [[Ascites]] | ||
Line 241: | Line 233: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 260: | Line 251: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 281: | Line 271: | ||
** Deletion 7q21-32 | ** Deletion 7q21-32 | ||
** Translocations of the CDK6 gene located on 7q21 | ** Translocations of the CDK6 gene located on 7q21 | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 308: | Line 297: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 332: | Line 320: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 369: | Line 356: | ||
* [[Petechiae]] | * [[Petechiae]] | ||
* [[Splenomegaly]] | * [[Splenomegaly]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 400: | Line 386: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Precursor T-cell Lymphomas | * Precursor T-cell Lymphomas | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 418: | Line 403: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 436: | Line 420: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 473: | Line 456: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Cutaneous manifestations | * Cutaneous manifestations | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 487: | Line 469: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 505: | Line 486: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 523: | Line 503: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 541: | Line 520: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 559: | Line 537: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 577: | Line 554: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | |
Revision as of 19:21, 17 January 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]
Category | Disease | Etiology | Clinical manifestations | Paraclinical findings | Gold standard | Associated findings | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lab findings | ||||||||||||||||
Symptoms | Signs | CBC | Immunochemistry | Histopathology | ||||||||||||
Constitutional symptoms | Rash | Abdominal pain | Diarrhea | Mass | Other | WBC | Hb | Plt | ||||||||
HL | ||||||||||||||||
Hodgkin's Lymphoma | ||||||||||||||||
NHL | ||||||||||||||||
B Cell Lymphoma | B-lymphoblastic leukemia/lymphoma |
|
+ | – | – | – |
|
↓ | ↓ | Nl to ↓ |
| |||||
Follicular lymphoma |
|
Only in 20% of patients: | + | + | ± |
|
↓ | ↓ | Nl to ↓ |
|
|
Lymph node biopsy |
| |||
Mantle cell lymphoma |
|
|
Abdominal distention |
|
|
|
↓ | Nl to ↓ |
|
|
||||||
Diffuse large B cell lymphoma |
|
|
|
↓ | ↓ | Nl to ↓ |
Centroblastic
Immunoblastic
Anaplastic
|
|||||||||
Disease | Etiology | Constitutional symptoms | Rash | Abdominal pain | Diarrhea | Mass | Other | WBC | Hb | Plt | Immunochemistry | Histopathology | Gold standard | Associated findings | ||
Burkitt lymphoma |
|
|
|
|
||||||||||||
B cell chronic lymphocytic leukemia/small lymphocytic lymphoma |
|
|||||||||||||||
Marginal zone lymphoma | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type |
|
||||||||||||||
Splenic marginal zone lymphoma |
|
|
||||||||||||||
Nodal marginal zone B-cell lymphoma |
|
+ |
|
|
| |||||||||||
Lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia) |
|
|||||||||||||||
Hairy cell leukemia |
|
|
|
|||||||||||||
T cell lymphoma | Precursor T-cell lymphoblastic leukemia/lymphoma |
|
||||||||||||||
Adult T cell leukemia/lymphoma |
|
|||||||||||||||
Anaplastic large cell lymphoma |
|
|||||||||||||||
Cutaneous T-cell lymphoma | Mycosis fungoides / Sézary syndrome |
|
|
|
||||||||||||
Peripheral T-cell lymphoma | Subcutaneous panniculitis-like T-cell lymphoma |
|
||||||||||||||
Hepatosplenic gamma-delta T-cell lymphoma |
|
|||||||||||||||
Enteropathy-type intestinal T-cell lymphoma |
|
|||||||||||||||
Extranodal T-cell lymphoma, nasal type |
|
|||||||||||||||
Angioimmunoblastic T-cell lymphoma |
|
|||||||||||||||
Peripheral T-cell lymphoma, unspecified |
|